{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,16]],"date-time":"2026-10-16T20:13:04Z","timestamp":1792181584772,"version":"4.4.0"},"reference-count":49,"publisher":"Springer Science and Business Media LLC","issue":"11","license":[{"start":{"date-parts":[[2023,9,22]],"date-time":"2023-09-22T00:00:00Z","timestamp":1695340800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2023,9,22]],"date-time":"2023-09-22T00:00:00Z","timestamp":1695340800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Mol Biol Rep"],"published-print":{"date-parts":[[2023,11]]},"DOI":"10.1007\/s11033-023-08760-3","type":"journal-article","created":{"date-parts":[[2023,9,22]],"date-time":"2023-09-22T08:02:56Z","timestamp":1695369776000},"page":"9511-9519","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":13,"title":["High-grade serous ovarian carcinoma, the \u201cAchiles\u2019 hill\u201d for clinicians and molecular biologists: a molecular insight"],"prefix":"10.1007","volume":"50","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-6613-8481","authenticated-orcid":false,"given":"Rittwika","family":"Bhattacharya","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Arijit","family":"Ghosh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Soma","family":"Mukhopadhyay","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2023,9,22]]},"reference":[{"issue":"4","key":"8760_CR1","doi-asserted-by":"publisher","first-page":"733","DOI":"10.1016\/j.ajpath.2015.11.011","volume":"186","author":"RJ Kurman","year":"2016","unstructured":"Kurman RJ, Shih IeM (2016) The dualistic model of ovarian carcinogenesis: revisited, revised, and expanded. Am J Pathol 186(4):733\u2013747. https:\/\/doi.org\/10.1016\/j.ajpath.2015.11.011","journal-title":"Am J Pathol"},{"key":"8760_CR2","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1186\/s13048-019-0484-6","volume":"12","author":"A Gadducci","year":"2019","unstructured":"Gadducci A, Guarneri V, Peccatori FA et al (2019) Current strategies for the targeted treatment of high-grade serous epithelial ovarian cancer and relevance of BRCA mutational status. J Ovarian Res 12:9. https:\/\/doi.org\/10.1186\/s13048-019-0484-6","journal-title":"J Ovarian Res"},{"key":"8760_CR3","doi-asserted-by":"publisher","first-page":"5496","DOI":"10.1111\/j.1742-4658.2008.06679.x","volume":"275","author":"WK So","year":"2008","unstructured":"So WK, Cheng JC, Poon SL, Leung PC (2008) Gonadotropin-releasing hormone and ovarian cancer: a functional and mechanistic overview. FEBS J 275:5496\u20135511. https:\/\/doi.org\/10.1111\/j.1742-4658.2008.06679.x","journal-title":"FEBS J"},{"key":"8760_CR4","doi-asserted-by":"publisher","first-page":"R35","DOI":"10.1530\/REP-14-0220","volume":"149","author":"D Bhartiya","year":"2015","unstructured":"Bhartiya D, Singh J (2015) FSH-FSHR3-stem cells in ovary surface epithelium: basis for adult ovarian biology, failure, aging, and cancer. Reproduction 149:R35\u2013R48. https:\/\/doi.org\/10.1530\/REP-14-0220","journal-title":"Reproduction"},{"key":"8760_CR5","first-page":"147","volume":"51","author":"CK Bose","year":"2001","unstructured":"Bose CK, Menon U, Thomas JM, Dawnay AB, Jacobs IJ (2001) Gonadotrophin levels in postmenopausal women with epithelial ovarian cancer. J Obstet Gynaecol India 51:147\u2013149","journal-title":"J Obstet Gynaecol India"},{"key":"8760_CR6","doi-asserted-by":"publisher","first-page":"1069","DOI":"10.1111\/j.1471-0528.2000.tb11102.x","volume":"107","author":"U Menon","year":"2000","unstructured":"Menon U, Riley SC, Thomas J, Bose C et al (2000) Serum inhibin, activin and follistatin in postmenopausal women with epithelial ovarian carcinoma. BJOG: Int J Obstet Gynaecol 107:1069\u20131074. https:\/\/doi.org\/10.1111\/j.1471-0528.2000.tb11102.x","journal-title":"BJOG: Int J Obstet Gynaecol"},{"key":"8760_CR7","doi-asserted-by":"publisher","first-page":"194","DOI":"10.1016\/S1472-6483(10)60958-3","volume":"11","author":"CK Bose","year":"2005","unstructured":"Bose CK (2005) Role of nerve growth factor and FSH receptor in epithelial ovarian cancer. Reprod Biomed Online 11:194\u2013197","journal-title":"Reprod Biomed Online"},{"key":"8760_CR8","first-page":"47","volume":"148","author":"W Zheng","year":"1996","unstructured":"Zheng W, Magid MS, Kramer EE, Chen YT (1996) Follicle-stimulating hormone receptor is expressed in human ovarian surface epithelium and fallopian tube. Am J Pathol 148:47\u201353","journal-title":"Am J Pathol"},{"key":"8760_CR9","doi-asserted-by":"publisher","first-page":"952","DOI":"10.3390\/ijms20040952","volume":"20","author":"MA Lisio","year":"2019","unstructured":"Lisio MA, Fu L, Goyeneche A, Gao ZH, Telleria C (2019) High-grade serous ovarian cancer: basic sciences, clinical and therapeutic standpoints. Int J Mol Sci 20:952. https:\/\/doi.org\/10.3390\/ijms20040952","journal-title":"Int J Mol Sci"},{"key":"8760_CR10","doi-asserted-by":"publisher","first-page":"e13029","DOI":"10.1111\/cpr.13029","volume":"54","author":"J Mei","year":"2021","unstructured":"Mei J, Tian H, Huang HS, Hsu CF (2021) Cellular models of development of ovarian high-grade serous carcinoma: a review of cell of origin and mechanisms of carcinogenesis. Cell Prolif 54:e13029. https:\/\/doi.org\/10.1111\/cpr.13029","journal-title":"Cell Prolif"},{"key":"8760_CR11","doi-asserted-by":"publisher","first-page":"13777","DOI":"10.3390\/ijms232213777","volume":"23","author":"P Punz\u00f3n-Jim\u00e9nez","year":"2022","unstructured":"Punz\u00f3n-Jim\u00e9nez P, Lago V, Domingo S, Sim\u00f3n C, Mas A (2022) Molecular management of high-grade serous ovarian carcinoma. Int J Mol Sci 23:13777. https:\/\/doi.org\/10.3390\/ijms232213777","journal-title":"Int J Mol Sci"},{"key":"8760_CR12","doi-asserted-by":"publisher","first-page":"66","DOI":"10.1002\/cncr.11476","volume":"98","author":"EV H\u00f8gdall","year":"2003","unstructured":"H\u00f8gdall EV, Christensen L, Kjaer SK, Blaakaer J et al (2003) Distribution of HER-2 overexpression in ovarian carcinoma tissue and its prognostic value in patients with ovarian carcinoma: from the danish MALOVA ovarian cancer study. Cancer 98:66\u201373. https:\/\/doi.org\/10.1002\/cncr.11476","journal-title":"Cancer"},{"key":"8760_CR13","doi-asserted-by":"publisher","first-page":"481","DOI":"10.1016\/j.jtcme.2021.03.005","volume":"11","author":"A Ghosh","year":"2021","unstructured":"Ghosh A, Roychowdhury T, Nandi R et al (2021) Inhibitory role of a smart nano-trifattyglyceride of Moringa oleifera root in epithelial ovarian cancer, through attenuation of FSHR-c-Myc axis. J Tradit Complement Med 11:481\u2013492. https:\/\/doi.org\/10.1016\/j.jtcme.2021.03.005","journal-title":"J Tradit Complement Med"},{"key":"8760_CR14","doi-asserted-by":"publisher","first-page":"371","DOI":"10.1016\/j.bbagen.2018.11.005","volume":"1863","author":"M Binju","year":"2019","unstructured":"Binju M, Padilla MA, Singomat T, Kaur P et al (2019) Mechanisms underlying acquired platinum resistance in high grade serous ovarian cancer\u2014a mini review. Biochim Biophys Acta Gen Subj 1863:371\u2013378. https:\/\/doi.org\/10.1016\/j.bbagen.2018.11.005","journal-title":"Biochim Biophys Acta Gen Subj"},{"key":"8760_CR15","doi-asserted-by":"publisher","first-page":"17996","DOI":"10.1038\/s41598-019-54401-w","volume":"9","author":"HD Reyes","year":"2019","unstructured":"Reyes HD, Devor EJ, Warrier A et al (2019) Differential DNA methylation in high-grade serous ovarian cancer (HGSOC) is associated with tumor behavior. Sci Rep 9:17996. https:\/\/doi.org\/10.1038\/s41598-019-54401-w","journal-title":"Sci Rep"},{"key":"8760_CR16","doi-asserted-by":"publisher","first-page":"3970","DOI":"10.1038\/s41467-018-05564-z","volume":"9","author":"O Kondrashova","year":"2018","unstructured":"Kondrashova O, Topp M, Nesic K, Lieschke E et al (2018) Methylation of all BRCA1 copies predicts response to the PARP inhibitor rucaparib in ovarian carcinoma. Nat Commun 9:3970. https:\/\/doi.org\/10.1038\/s41467-018-05564-z","journal-title":"Nat Commun"},{"key":"8760_CR17","doi-asserted-by":"publisher","DOI":"10.1080\/15592294.2020.1853402","author":"H Cardenas","year":"2020","unstructured":"Cardenas H, Fang F, Jiang G, Perkins SM et al (2020) Methylomic signatures of high grade serous ovarian cancer. Epigenetics. https:\/\/doi.org\/10.1080\/15592294.2020.1853402","journal-title":"Epigenetics"},{"key":"8760_CR18","doi-asserted-by":"publisher","first-page":"142","DOI":"10.1186\/s13148-021-01130-5","volume":"13","author":"DW Chan","year":"2021","unstructured":"Chan DW, Lam WY, Chen F, Yung MMH et al (2021) Genome-wide DNA methylome analysis identifies methylation signatures associated with survival and drug resistance of ovarian cancers. Clin Epigenetics 13:142. https:\/\/doi.org\/10.1186\/s13148-021-01130-5","journal-title":"Clin Epigenetics"},{"key":"8760_CR19","doi-asserted-by":"publisher","first-page":"5993","DOI":"10.3390\/cancers13235993","volume":"13","author":"BG Matthews","year":"2021","unstructured":"Matthews BG, Bowden NA, Wong-Brown MW (2021) Epigenetic mechanisms and therapeutic targets in chemoresistant high-grade serous ovarian cancer. Cancers 13:5993. https:\/\/doi.org\/10.3390\/cancers13235993","journal-title":"Cancers"},{"key":"8760_CR20","doi-asserted-by":"publisher","first-page":"4335","DOI":"10.1158\/0008-5472.CAN-20-0521","volume":"80","author":"L Geistlinger","year":"2020","unstructured":"Geistlinger L, Oh S, Ramos M, Schiffer L et al (2020) Multiomic analysis of subtype evolution and heterogeneity in high-grade serous ovarian carcinoma. Cancer Res 80:4335\u20134345. https:\/\/doi.org\/10.1158\/0008-5472.CAN-20-0521","journal-title":"Cancer Res"},{"key":"8760_CR21","doi-asserted-by":"publisher","first-page":"3726","DOI":"10.1016\/j.celrep.2019.10.122","volume":"29","author":"K Lawrenson","year":"2019","unstructured":"Lawrenson K, Fonseca MAS, Liu AY, Segato Dezem F et al (2019) A study of high-grade serous ovarian cancer origins implicates the SOX18 transcription factor in tumor development. Cell Rep 29:3726-3735. https:\/\/doi.org\/10.1016\/j.celrep.2019.10.122","journal-title":"Cell Rep"},{"key":"8760_CR22","doi-asserted-by":"publisher","first-page":"6","DOI":"10.1186\/s43046-022-00104-9","volume":"34","author":"M Khashaba","year":"2022","unstructured":"Khashaba M, Fawzy M, Abdel-Aziz A et al (2022) Subtyping of high grade serous ovarian carcinoma: histopathological and immunohistochemical approach. J Egypt Natl Canc Inst 34:6. https:\/\/doi.org\/10.1186\/s43046-022-00104-9","journal-title":"J Egypt Natl Canc Inst"},{"key":"8760_CR23","doi-asserted-by":"publisher","first-page":"1051","DOI":"10.1002\/emmm.201201823","volume":"5","author":"TZ Tan","year":"2013","unstructured":"Tan TZ, Miow QH, Huang RY, Wong MK et al (2013) Functional genomics identifies five distinct molecular subtypes with clinical relevance and pathways for growth control in epithelial ovarian cancer. EMBO Mol Med 5:1051\u20131066. https:\/\/doi.org\/10.1002\/emmm.201201823","journal-title":"EMBO Mol Med"},{"key":"8760_CR24","doi-asserted-by":"publisher","first-page":"16","DOI":"10.1016\/j.ejcsup.2019.11.001","volume":"15","author":"A Mota","year":"2020","unstructured":"Mota A, Oltra S, Moreno-Bueno S G (2020) Insight updating of the molecular hallmarks in ovarian carcinoma. EJC Suppl 15:16\u201326. https:\/\/doi.org\/10.1016\/j.ejcsup.2019.11.001","journal-title":"EJC Suppl"},{"key":"8760_CR25","doi-asserted-by":"publisher","first-page":"1262","DOI":"10.1038\/s41588-018-0179-8","volume":"50","author":"G Macintyre","year":"2018","unstructured":"Macintyre G, Goranova TE, De Silva D et al (2018) Copy number signatures and mutational processes in ovarian carcinoma. Nat Genet 50:1262\u20131270. https:\/\/doi.org\/10.1038\/s41588-018-0179-8","journal-title":"Nat Genet"},{"key":"8760_CR26","doi-asserted-by":"publisher","first-page":"1544","DOI":"10.3390\/antiox11081544","volume":"11","author":"D Criscuolo","year":"2022","unstructured":"Criscuolo D, Avolio R, Parri M, Romano S, Chiarugi P, Matassa DS, Esposito F (2022) Decreased levels of GSH are associated with platinum resistance in high-grade serous ovarian cancer. Antioxid 11:1544. https:\/\/doi.org\/10.3390\/antiox11081544","journal-title":"Antioxid"},{"key":"8760_CR27","doi-asserted-by":"publisher","first-page":"573","DOI":"10.20517\/cdr.2021.05","volume":"4","author":"N Rinne","year":"2021","unstructured":"Rinne N, Christie EL, Ardasheva A, Kwok CH et al (2021) Targeting the PI3K\/AKT\/mTOR pathway in epithelial ovarian cancer, therapeutic treatment options for platinum-resistant ovarian cancer. Cancer Drug Resist 4:573\u2013595. https:\/\/doi.org\/10.20517\/cdr.2021.05","journal-title":"Cancer Drug Resist"},{"key":"8760_CR28","doi-asserted-by":"publisher","first-page":"5213","DOI":"10.2147\/CMAR.S251622","volume":"12","author":"Y Wu","year":"2020","unstructured":"Wu Y, Xia L, Guo Q, Zhu J, Deng Y, Wu X (2020) Identification of chemoresistance-associated key genes and pathways in high-grade serous ovarian cancer by bioinformatics analyses. Cancer Manag Res 12:5213\u20135223. https:\/\/doi.org\/10.2147\/CMAR.S251622","journal-title":"Cancer Manag Res"},{"key":"8760_CR29","doi-asserted-by":"publisher","first-page":"2349","DOI":"10.18632\/oncotarget.2957","volume":"6","author":"WT Chiu","year":"2015","unstructured":"Chiu WT, Huang YF, Tsai HY, Chen CC et al (2015) FOXM1 confers to epithelial-mesenchymal transition, stemness and chemoresistance in epithelial ovarian carcinoma cells. Oncotarget 6:2349\u20132365. https:\/\/doi.org\/10.18632\/oncotarget.2957","journal-title":"Oncotarget"},{"key":"8760_CR30","doi-asserted-by":"publisher","first-page":"42","DOI":"10.1186\/s12929-020-00638-x","volume":"27","author":"CH Fang","year":"2020","unstructured":"Fang CH, Lin YT, Liang CM, Liang SM (2020) A novel c-Kit\/phospho-prohibitin axis enhances ovarian cancer stemness and chemoresistance via Notch3-PBX1 and \u03b2-catenin-ABCG2 signaling. J Biomed Sci 27:42. https:\/\/doi.org\/10.1186\/s12929-020-00638-x","journal-title":"J Biomed Sci"},{"key":"8760_CR31","doi-asserted-by":"publisher","first-page":"2767","DOI":"10.1038\/onc.2012.290","volume":"32","author":"WK Chau","year":"2013","unstructured":"Chau WK, Ip CK, Mak AS, Lai HC, Wong AS (2013) c-Kit mediates chemoresistance and tumor-initiating capacity of ovarian cancer cells through activation of Wnt\/\u03b2-catenin-ATP-binding cassette G2 signaling. Oncogene 32:2767\u20132781. https:\/\/doi.org\/10.1038\/onc.2012.290","journal-title":"Oncogene"},{"key":"8760_CR32","doi-asserted-by":"publisher","first-page":"2901","DOI":"10.3390\/ijms19102901","volume":"19","author":"K Sterzy\u0144ska","year":"2018","unstructured":"Sterzy\u0144ska K, Klejewski A, Wojtowicz K, \u015awierczewska M et al (2018) The role of matrix gla protein (MGP) expression in paclitaxel and topotecan resistant ovarian cancer cell lines. Int J Mol Sci 19:2901. https:\/\/doi.org\/10.3390\/ijms19102901","journal-title":"Int J Mol Sci"},{"key":"8760_CR33","doi-asserted-by":"publisher","first-page":"596","DOI":"10.20517\/cdr.2021.20","volume":"4","author":"A Romagnoli","year":"2021","unstructured":"Romagnoli A, Maracci C, D\u2019Agostino M, Teana A, Marino DD (2021) Targeting mTOR and eIF4E: a feasible scenario in ovarian cancer therapy. Cancer Drug Resist 4:596\u2013606. https:\/\/doi.org\/10.20517\/cdr.2021.20","journal-title":"Cancer Drug Resist"},{"key":"8760_CR34","doi-asserted-by":"publisher","first-page":"1369","DOI":"10.3390\/cancers13061369","volume":"13","author":"MS Chesnokov","year":"2021","unstructured":"Chesnokov MS, Khan I, Park Y, Ezell J et al (2021) The MEK1\/2 pathway as a therapeutic target in high-grade serous ovarian carcinoma. Cancers 13:1369. https:\/\/doi.org\/10.3390\/cancers13061369","journal-title":"Cancers"},{"key":"8760_CR35","doi-asserted-by":"publisher","first-page":"584","DOI":"10.1007\/s10637-019-00803-6","volume":"38","author":"J Dini\u0107","year":"2020","unstructured":"Dini\u0107 J, R\u00edos-Luci C, Karpaviciene I, Cikotiene I et al (2020) CKT0353, a novel microtubule targeting agent, overcomes paclitaxel induced resistance in cancer cells. Invest New Drugs 38:584\u2013598. https:\/\/doi.org\/10.1007\/s10637-019-00803-6","journal-title":"Invest New Drugs"},{"key":"8760_CR36","doi-asserted-by":"publisher","first-page":"404","DOI":"10.3892\/ijo.2018.4401","volume":"53","author":"L Shen","year":"2018","unstructured":"Shen L, Sun B, Sheng J, Yu S et al (2018) PGC1\u03b1 promotes cisplatin resistance in human ovarian carcinoma cells through upregulation of mitochondrial biogenesis. Int J Oncol 53:404\u2013416. https:\/\/doi.org\/10.3892\/ijo.2018.4401","journal-title":"Int J Oncol"},{"key":"8760_CR37","doi-asserted-by":"publisher","first-page":"22","DOI":"10.1186\/1757-2215-5-22","volume":"5","author":"C Peracchio","year":"2012","unstructured":"Peracchio C, Alabiso O, Valente G, Isidoro C (2012) Involvement of autophagy in ovarian cancer: a working hypothesis. J Ovarian Res 5:22. https:\/\/doi.org\/10.1186\/1757-2215-5-22","journal-title":"J Ovarian Res"},{"key":"8760_CR38","doi-asserted-by":"publisher","first-page":"12","DOI":"10.1038\/s41420-020-0246-7","volume":"6","author":"B Zhao","year":"2020","unstructured":"Zhao B, Dierichs L, Gu JN, Trajkovic-Arsic M et al (2020) TFEB-mediated lysosomal biogenesis and lysosomal drug sequestration confer resistance to MEK inhibition in pancreatic cancer. Cell Death Discov 6:12. https:\/\/doi.org\/10.1038\/s41420-020-0246-7","journal-title":"Cell Death Discov"},{"key":"8760_CR39","doi-asserted-by":"publisher","first-page":"18","DOI":"10.1038\/s41389-018-0033-y","volume":"7","author":"S Manousakidi","year":"2018","unstructured":"Manousakidi S, Guillaume A, Pirou C, Bouleau S et al (2018) FGF1 induces resistance to chemotherapy in ovarian granulosa tumor cells through regulation of p53 mitochondrial localization. Oncogenesis 7:18. https:\/\/doi.org\/10.1038\/s41389-018-0033-y","journal-title":"Oncogenesis"},{"key":"8760_CR40","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0059083","author":"MT Lau","year":"2013","unstructured":"Lau MT, So WK, Leung PCK (2013) Correction: fibroblast growth factor 2 induces E-cadherin down-regulation via PI3K\/Akt\/mTOR and MAPK\/ERK signaling in ovarian cancer cells. PLoS ONE. https:\/\/doi.org\/10.1371\/journal.pone.0059083","journal-title":"PLoS ONE"},{"key":"8760_CR41","doi-asserted-by":"publisher","first-page":"689","DOI":"10.1007\/s00018-017-2686-7","volume":"75","author":"D Ostroumov","year":"2018","unstructured":"Ostroumov D, Fekete-Drimusz N, Saborowski M et al (2018) CD4 and CD8 T lymphocyte interplay in controlling tumor growth. Cell Mol Life Sci 75:689\u2013713. https:\/\/doi.org\/10.1007\/s00018-017-2686-7","journal-title":"Cell Mol Life Sci"},{"key":"8760_CR42","doi-asserted-by":"publisher","first-page":"127","DOI":"10.1038\/s41392-021-00506-6","volume":"6","author":"Z Duan","year":"2021","unstructured":"Duan Z, Luo Y (2021) Targeting macrophages in cancer immunotherapy. Sig Transduct Target Ther 6:127. https:\/\/doi.org\/10.1038\/s41392-021-00506-6","journal-title":"Sig Transduct Target Ther"},{"key":"8760_CR43","doi-asserted-by":"publisher","first-page":"369","DOI":"10.1038\/s41577-019-0127-6","volume":"19","author":"DG DeNardo","year":"2019","unstructured":"DeNardo DG, Ruffell B (2019) Macrophages as regulators of tumour immunity and immunotherapy. Nat Rev Immunol 19:369\u2013382. https:\/\/doi.org\/10.1038\/s41577-019-0127-6","journal-title":"Nat Rev Immunol"},{"key":"8760_CR44","doi-asserted-by":"publisher","first-page":"e130850","DOI":"10.1172\/jci.insight.130850","volume":"4","author":"J Kargl","year":"2019","unstructured":"Kargl J, Zhu X, Zhang H, Yang GHY et al (2019) Neutrophil content predicts lymphocyte depletion and anti-PD1 treatment failure in NSCLC. JCI Insight 4:e130850. https:\/\/doi.org\/10.1172\/jci.insight.130850","journal-title":"JCI Insight"},{"key":"8760_CR45","doi-asserted-by":"publisher","first-page":"625783","DOI":"10.3389\/fimmu.2021.625783","volume":"12","author":"JM Gonz\u00e1lez-Navajas","year":"2021","unstructured":"Gonz\u00e1lez-Navajas JM, Fan DD, Yang S, Yang FM et al (2021) The impact of tregs on the anticancer immunity and the efficacy of immune checkpoint inhibitor therapies. Front Immunol 12:625783. https:\/\/doi.org\/10.3389\/fimmu.2021.625783","journal-title":"Front Immunol"},{"key":"8760_CR46","doi-asserted-by":"publisher","first-page":"1999","DOI":"10.3389\/fimmu.2019.01999","volume":"10","author":"J Bi","year":"1999","unstructured":"Bi J, Tian Z (1999) NK cell dysfunction and checkpoint immunotherapy. Front Immunol 10:1999. https:\/\/doi.org\/10.3389\/fimmu.2019.01999","journal-title":"Front Immunol"},{"key":"8760_CR47","doi-asserted-by":"publisher","first-page":"1720","DOI":"10.1016\/j.cell.2018","volume":"175","author":"JB Haanen","year":"2018","unstructured":"Haanen JB, Cerundolo V (2018) NKG2A, a new kid on the immune checkpoint block. Cell 175:1720\u20131722. https:\/\/doi.org\/10.1016\/j.cell.2018","journal-title":"Cell"},{"key":"8760_CR48","doi-asserted-by":"publisher","first-page":"88","DOI":"10.1186\/s40425-018-0401-3","volume":"6","author":"G Xie","year":"2018","unstructured":"Xie G, Cheng T, Lin J, Zhang L et al (2018) Local angiotensin II contributes to tumor resistance to checkpoint immunotherapy. J Immunother Cancer 6:88. https:\/\/doi.org\/10.1186\/s40425-018-0401-3","journal-title":"J Immunother Cancer"},{"key":"8760_CR49","doi-asserted-by":"publisher","first-page":"154074","DOI":"10.1016\/j.prp.2022.154074","volume":"238","author":"J Tao","year":"2022","unstructured":"Tao J, Sun D, Zhou H, Zhu J et al (2022) Next-generation sequencing identifies potential novel therapeutic targets in chinese HGSOC patients. Pathol Res Pract 238:154074. https:\/\/doi.org\/10.1016\/j.prp.2022.154074","journal-title":"Pathol Res Pract"}],"container-title":["Molecular Biology Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11033-023-08760-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s11033-023-08760-3\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11033-023-08760-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,11,9]],"date-time":"2023-11-09T07:28:36Z","timestamp":1699514916000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s11033-023-08760-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,9,22]]},"references-count":49,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2023,11]]}},"alternative-id":["8760"],"URL":"https:\/\/doi.org\/10.1007\/s11033-023-08760-3","relation":{},"ISSN":["0301-4851","1573-4978"],"issn-type":[{"value":"0301-4851","type":"print"},{"value":"1573-4978","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,9,22]]},"assertion":[{"value":"4 December 2022","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 August 2023","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"22 September 2023","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Authors declare that there is no potential conflict of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"The manuscript complies with the Ethical Rules applicable for this journal.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}},{"value":"This article does not contain any studies with animals performed by any of the authors.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Research involving human and animal participants"}}]}}